/
We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted m…
$3.21
+$0.09 (+3.05%)
Price from 28 days ago
The business is unprofitable at the operating level (-4498.06% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 55.3% YoY with margins expanding 2289.3pp.
Negative free cash flow of -$167M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$5M
▲ +55.3% YoY
Net Income (TTM)
-$198M
▼ -2.7% YoY
Op. Margin
-4498.06%
▲ +2289.3pp YoY
ROIC
-73.44%
▲ +17.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$159M
▼ -28.4% YoY
Op. Cash Flow (TTM)
-$156M
▼ -32.3% YoY
Net Debt
-$21M
Net Cash Position
Cash & Equiv.
$135M
5Y CAGR: -2.3%
Continue Research